TIKTOK
6.9.2018 12:57:28 CEST | Business Wire | Press release
TikTok, the go-to destination for the creating and viewing short-term mobile videos, has arrived in the global capital of fashion: Paris. The worldwide phenomenon held its first event on Tuesday September 4 during a unique night on the Seine. With its “80’s vs 2080 theme, TikTok took its community on a creative and innovative adventure, like its platform. The brand also welcomed today’s most creative influencers to celebrate the arrival of the new TikTok platform, born from the union with the Musical.ly app, and has thus unveiled application’s new innovative features and technological innovations of the application, such as "reaction" function that allows users to react directly to their friends' videos.
TikTok : a new groundbreaking upgrade
A global platform now
present in more than 150 countries and regions, TikTok was one of the
most downloaded applications in the world in early 20181
. The
latest update, which incorporates the best of both applications, has
allowed TikTok to creatively connect its community in a multicultural
environment. The newly upgraded platform, offers greater capabilities
for video creation and allows creators to enjoy the opportunity to reach
a bigger and more diverse global audience. By providing an intuitive,
creative and personalized visualization experience, TikTok enables its
community to create and discover tomorrow's trends
Chenyi Qiu, Director of TikTok Operations in West Europe, said: "The rebranding of TikTok in Europe marks a new milestone for us! Through this event we wish to celebrate the diversity of our platform and thus put creativity in the spotlight in different sectors. That is why we approach the theme of sustainable fashion with our community. "
TikTok inspires the best creators and influencers
For the
launch of the new TikTok platform in France, the application paid
tribute to the creativity of its community by organizing original
workshops. To make this moment a memorable evening, TikTok partnered
with the best, and invited creators from different horizons: fashion,
music, dance, makeup, ...
Claire Dartigues, fashion designer and finalist of the 2017 Redress Award, gave a workshop on the importance of sustainable fashion. Claire also inspired her audience by showing them how to create a unique and original outfit entirely made of recyclable materials. During another workshop, TikTok’s influencers and creators unveiled the breadth of their creativity and shared their best tips for creating innovative and creative videos.
Much more than just videos!
With the help of many
influencers including Youtuber Shera
Kerienski
and influencer Estelle
Fitz
, the app unveiled many of the application’s new features.
TikTok presented the "reaction" function
which allows
the user to react directly to their friends’ videos on their phone. This
innovative technology allows users to interact with videos by
integrating their reactions into the content they are viewing. The
platform also unveiled its new
interactive filters made possible by artificial intelligence
,
allowing users to apply filters to their entire body and trigger new
special effects. Rachel
Ward
, famous influencer from TikTok, said : "TikTok is a great app
because it gave me the courage to be myself and have fun the community
is supportive, friendly and diverse."
About TikTok
TikTok is a
destination for short-form mobile videos. Our mission is to capture and
present the world's creativity, knowledge, and moments that matter,
directly from the mobile phone. TikTok enables everyone to be a creator
and encourages users to share their passion and creative expression
through their videos. TikTok is based in Los Angeles, with global
offices in London, Tokyo, Seoul, Shanghai, Beijing, Singapore, Jakarta,
Mumbai, and Moscow. In early 2018, TikTok was one of the most downloaded
apps in the world. TikTok is available worldwide for iOS
and Android
. Visit tiktok.com
.
1 Sensor tower, 1Q report
View source version on businesswire.com: https://www.businesswire.com/news/home/20180906005390/en/
Contact:
Agence Burson Cohn&Wolfe Giulia Goodwin - Charlotte Durand tiktokfr@cohnwolfe.com +33 (0)1 56 03 13 83 / +33 (0)6 28 79 11 40 +33 1 56 03 13 66
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom